{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T18:15:41Z","timestamp":1775240141763,"version":"3.50.1"},"reference-count":53,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,5,23]],"date-time":"2022-05-23T00:00:00Z","timestamp":1653264000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cardiovasc. Med."],"abstract":"<jats:p>Cardiovascular disease, in particular ischemic heart disease is a major cause of morbidity and mortality worldwide. Primary aldosteronism is the leading cause of secondary hypertension, yet commonly under diagnosed, and represents a major preventable risk factor. In contrast to historical teaching, recent studies have shown that excess aldosterone production is associated with increased burden of ischemic heart disease disproportionate to the effects caused by hypertension alone. Aldosterone through its genomic and non-genomic actions exerts various detrimental cardiovascular changes contributing to this elevated risk. Recognition of primary hyperaldosteronism and understanding the distinctive pathophysiology of ischemic heart disease in primary aldosteronism is crucial to develop strategies to improve outcomes.<\/jats:p>","DOI":"10.3389\/fcvm.2022.882330","type":"journal-article","created":{"date-parts":[[2022,5,23]],"date-time":"2022-05-23T05:02:05Z","timestamp":1653282125000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":9,"title":["Primary Aldosteronism and Ischemic Heart Disease"],"prefix":"10.3389","volume":"9","author":[{"given":"Shivaraj","family":"Patil","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chaitanya","family":"Rojulpote","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aman","family":"Amanullah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2022,5,23]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"2529","DOI":"10.1016\/j.jacc.2019.10.009","article-title":"The global burden of cardiovascular diseases and risk factors: 2020 and beyond","volume":"74","author":"Mensah","year":"2019","journal-title":"J Am Coll Cardiol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"e005375","DOI":"10.1161\/CIRCOUTCOMES.118.005375","article-title":"Mortality from ischemic heart disease","volume":"12","author":"Nowbar","year":"2019","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"B3","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1161\/CIRCULATIONAHA.115.018912","article-title":"Global disparities of hypertension prevalence and control: a systematic analysis of population-based studies from 90 countries","volume":"134","author":"Mills","year":"2016","journal-title":"Circulation."},{"key":"B4","doi-asserted-by":"publisher","first-page":"e435","DOI":"10.1161\/CIR.0000000000000207","article-title":"Treatment of hypertension in patients with coronary artery disease: a scientific statement from the American Heart Association, American College of Cardiology, and American Society of Hypertension","volume":"131","author":"Rosendorff","year":"2015","journal-title":"Circulation."},{"key":"B5","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1056\/NEJMoa033263","article-title":"Serum aldosterone and the insidence of hypertension in nonhypertensive persons","volume":"351","author":"Vasan","year":"2004","journal-title":"N Engl Med."},{"key":"B6","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1038\/s41371-020-0336-2","article-title":"Primary aldosteronism is a public health issue: challenges and opportunities","volume":"34","author":"Libianto","year":"2020","journal-title":"J Hum Hypertens."},{"key":"B7","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1007\/s11906-013-0330-y","article-title":"Aldosterone and the risk of hypertension","volume":"15","author":"Xanthakis","year":"2013","journal-title":"Curr Hypertens Rep."},{"key":"B8","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1001\/archinternmed.2007.33","article-title":"Cardiovascular outcomes in patients with primary aldosteronism after treatment","volume":"168","author":"Catena","year":"2008","journal-title":"Arch Int Med."},{"key":"B9","doi-asserted-by":"publisher","first-page":"e15985","DOI":"10.1097\/MD.0000000000015985","article-title":"Cardiovascular risk in primary aldosteronism: a systematic review and meta-analysis","volume":"98","author":"Wu","year":"2019","journal-title":"Medicine."},{"key":"B10","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1161\/HYPERTENSIONAHA.117.10263","article-title":"Prevalence of cardiovascular disease and its risk factors in primary aldosteronism: a multicenter study in Japan","volume":"71","author":"Ohno","year":"2018","journal-title":"Hypertension."},{"key":"B11","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1161\/HYPERTENSIONAHA.113.01060","article-title":"Cardiovascular complications associated with primary aldosteronism: a controlled cross-sectional study","volume":"62","author":"Savard","year":"2013","journal-title":"Hypertension."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1210\/jc.2008-2116","article-title":"Participants of the German conn's registry. cardiovascular and cerebrovascular comorbidities of hypokalemic and normokalemic primary aldosteronism: results of the German Conn's Registry","volume":"94","author":"Born-Frontsberg","year":"2009","journal-title":"J Clin Endocrinol Metab."},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1152\/ajpheart.00283.2011","article-title":"A role for cardiotrophin-1 in myocardial remodeling induced by aldosterone","author":"L\u00f3pez-Andr\u00e9s","year":"2011","journal-title":"Am J Physiol Heart Circul Physiol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1016\/j.cardfail.2004.03.002","article-title":"O\u2032 Connell Td, et al. Aldosterone directly stimulates cardiac myocyte hypertrophy","volume":"10","author":"Okoshi","year":"2004","journal-title":"J Card Fail."},{"key":"B15","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1038\/s41371-020-00426-y","article-title":"Left ventricular remodeling and dysfunction in primary aldosteronism","volume":"35","author":"Tsai","year":"2021","journal-title":"J Hum Hypertens."},{"key":"B16","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1177\/0267659117727826","article-title":"Left ventricular dysfunction causing ischemia in patients with patent coronary arteries","volume":"33","author":"Nguyen","year":"2018","journal-title":"Perfusion."},{"key":"B17","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1161\/01.CIR.102.4.470","article-title":"Left ventricular hypertrophy: pathogenesis, detection, and prognosis","volume":"102","author":"Lorell","year":"2000","journal-title":"Circulation."},{"key":"B18","doi-asserted-by":"publisher","first-page":"5214","DOI":"10.3390\/ijms20205214","article-title":"Endothelial dysfunction in primary aldosteronism","volume":"20","author":"Chen","year":"2019","journal-title":"Int J Mol Sci."},{"key":"B19","doi-asserted-by":"publisher","first-page":"46","DOI":"10.2174\/1573402113666170228151402","article-title":"Vascular consequences of aldosterone excess and mineralocorticoid receptor antagonism","volume":"13","author":"Chrissobolis","year":"2017","journal-title":"Curr Hypertens Rev."},{"key":"B20","doi-asserted-by":"publisher","first-page":"34","DOI":"10.4103\/HEARTVIEWS.HEARTVIEWS_37_17","article-title":"Diabetes as \u201ccoronary artery disease risk equivalent\u201d: a historical perspective","volume":"18","author":"Hajar","year":"2017","journal-title":"Heart Views."},{"key":"B21","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/S2213-8587(17)30319-4","article-title":"Cardiovascular events and target organ damage in primary aldosteronism compared with essential hypertension: a systematic review and meta-analysis","volume":"6","author":"Monticone","year":"2018","journal-title":"Lancet Diabetes Endocrinol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1210\/jc.2005-1733","article-title":"Prevalence and characteristics of the metabolic syndrome in primary aldosteronism","volume":"91","author":"Fallo","year":"2006","journal-title":"J Clin Endocrinol Metab."},{"key":"B23","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1161\/HYPERTENSIONAHA.114.04981","article-title":"Adipocyte mineralocorticoid receptor activation leads to metabolic syndrome and induction of prostaglandin D2 synthase","volume":"66","author":"Urbanet","year":"2015","journal-title":"Hypertension."},{"key":"B24","doi-asserted-by":"publisher","first-page":"4456","DOI":"10.1210\/jc.2018-00866","article-title":"Obesity as a key factor underlying idiopathic hyperaldosteronism","volume":"103","author":"Ohno","year":"2018","journal-title":"J Clin Endocrinol Metab."},{"key":"B25","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.steroids.2014.08.016","article-title":"Effects of aldosterone on insulin sensitivity and secretion","volume":"91","author":"Luther","year":"2014","journal-title":"Steroids."},{"key":"B26","doi-asserted-by":"publisher","first-page":"236","DOI":"10.2337\/db14-0670","article-title":"Mineralocorticoid receptor blockade improves coronary microvascular function in individuals with type 2 diabetes","volume":"64","author":"Garg","year":"2015","journal-title":"Diabetes."},{"key":"B27","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1161\/HYPERTENSIONAHA.118.11568","article-title":"Renal outcomes in medically and surgically treated primary aldosteronism","volume":"72","author":"Hundemer","year":"2018","journal-title":"Hypertension."},{"key":"B28","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1161\/01.HYP.0000102971.85504.7c","article-title":"American Heart Association Councils on kidney in cardiovascular disease, high blood pressure research, clinical cardiology, and epidemiology and prevention. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention","volume":"42","author":"Sarnak","year":"2003","journal-title":"Hypertension."},{"key":"B29","doi-asserted-by":"publisher","first-page":"3192","DOI":"10.1210\/jc.2019-00299","article-title":"Impaired glucose metabolism in primary aldosteronism is associated with cortisol cosecretion","volume":"104","author":"Gerards","year":"2019","journal-title":"J Clin Endocrinol Metab."},{"key":"B30","doi-asserted-by":"publisher","first-page":"4543","DOI":"10.1210\/jc.2018-00617","article-title":"Cortisol excess in patients with primary aldosteronism impacts left ventricular hypertrophy","volume":"103","author":"Adolf","year":"2018","journal-title":"J Clin Endocrinol Metab."},{"key":"B31","doi-asserted-by":"publisher","first-page":"3617","DOI":"10.1210\/jcem.80.12.8530609","article-title":"11 Beta-hydroxysteroid dehydrogenase activity in cushing's syndrome: explaining the mineralocorticoid excess state of the ectopic adrenocorticotropin syndrome","volume":"80","author":"Stewart","year":"1995","journal-title":"J Clin Endocrinol Metabol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1210\/en.2010-0925","article-title":"11\u03b2-hydroxysteroid dehydrogenase type 2 deficiency accelerates atherogenesis and causes proinflammatory changes in the endothelium in Apoe\u2013\/\u2013 mice","volume":"152","author":"Deuchar","year":"2011","journal-title":"Endocrinology."},{"key":"B33","doi-asserted-by":"publisher","first-page":"2045","DOI":"10.1210\/jc.2012-3754","article-title":"Hypercortisolism is associated with increased coronary arterial atherosclerosis: analysis of noninvasive coronary angiography using multidetector computerized tomography","volume":"98","author":"Neary","year":"2013","journal-title":"J Clin Endocrinol Metab."},{"key":"B34","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1161\/HYPERTENSIONAHA.120.15328","article-title":"Presence of subclinical hypercortisolism in clinical aldosterone-producing adenomas predicts lower clinical success","volume":"76","author":"Peng","year":"2020","journal-title":"Hypertension."},{"key":"B35","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1373\/clinchem.2012.199729","article-title":"Inhibition of the renin-angiotensin system reduces the rise in serum aldosterone in acute coronary syndrome patients with preserved left ventricular function: observations from the avant garde-timi 43 trial","volume":"59","author":"Udell","year":"2013","journal-title":"Clin Chem."},{"key":"B36","doi-asserted-by":"publisher","first-page":"27","DOI":"10.2459\/JCM.0b013e328364129c","article-title":"Prognostic role of aldosterone in patients with acute coronary syndrome: short and medium term follow-up","volume":"15","author":"Mignano","year":"2014","journal-title":"J Cardiovasc Med."},{"key":"B37","doi-asserted-by":"publisher","first-page":"2604","DOI":"10.1161\/CIRCULATIONAHA.106.634626","article-title":"High plasma aldosterone levels on admission are associated with death in patients presenting with acute st-elevation myocardial infarction","volume":"114","author":"Beygui","year":"2006","journal-title":"Circulation."},{"key":"B38","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.amjcard.2006.03.004","article-title":"Cardiovascular effects of aldosterone and post\u2013acute myocardial infarction pathophysiology","volume":"97","author":"Cohn","year":"2006","journal-title":"Am J Cardiol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1161\/01.CIR.0000138973.55605.38","article-title":"Mineralocorticoid receptor antagonism prevents the electrical remodeling that precedes cellular hypertrophy after myocardial infarction","volume":"110","author":"Perrier","year":"2004","journal-title":"Circulation."},{"key":"B40","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1056\/NEJMoa030207","article-title":"Eplerenone post-acute myocardial infarction heart failure efficacy and survival study investigators: eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction","volume":"348","author":"Pitt","year":"2003","journal-title":"N Engl J Med."},{"key":"B41","doi-asserted-by":"publisher","first-page":"2354","DOI":"10.1161\/CIR.0000000000000133","article-title":"2014 Aha\/Acc guideline for the management of patients with non\u2013st-elevation acute coronary syndromes: executive summary: a report of the American College of Cardiology\/American Heart Association Task Force on practice guidelines","volume":"130","author":"Amsterdam","year":"2014","journal-title":"Circulation."},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0b013e3182742c84","article-title":"2013 Accf\/Aha Guideline for the Management of St-elevation myocardial infarction: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines","author":"O'gara","year":"2013","journal-title":"J Am Coll Cardiol."},{"key":"B43","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.ahj.2019.02.005","article-title":"Mineralocorticoid receptor antagonist pre-treatment and early post-treatment to minimize reperfusion injury after st-elevation myocardial infarction: the minimize stemi trial","volume":"211","author":"Bulluck","year":"2019","journal-title":"Am Heart J."},{"key":"B44","doi-asserted-by":"publisher","first-page":"1917","DOI":"10.1016\/j.jacc.2016.02.033","article-title":"Early aldosterone blockade in acute myocardial infarction: the albatross randomized clinical trial","volume":"67","author":"Beygui","year":"2016","journal-title":"J Am Coll Cardiol."},{"key":"B45","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1093\/eurheartj\/ehu164","article-title":"Early eplerenone treatment in patients with acute st-elevation myocardial infarction without heart failure: the randomized double-blind reminder study","volume":"35","author":"Montalescot","year":"2014","journal-title":"Eur Heart J."},{"key":"B46","doi-asserted-by":"publisher","first-page":"644260","DOI":"10.3389\/fendo.2021.644260","article-title":"Composite cardiovascular outcomes in patients with primary aldosteronism undergoing medical versus surgical treatment: a meta-analysis","volume":"12","author":"Huang","year":"2021","journal-title":"Front Endocrinol."},{"key":"B47","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/S2213-8587(17)30367-4","article-title":"Cardiometabolic outcomes and mortality in medically treated primary aldosteronism: a retrospective cohort study","volume":"6","author":"Hundemer","year":"2018","journal-title":"Lancet Diabetes Endocrinol."},{"key":"B48","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1161\/CIRCOUTCOMES.115.002002","article-title":"Cost-effectiveness of screening for primary aldosteronism and subtype diagnosis in the resistant hypertensive patients","volume":"8","author":"Lubitz","year":"2015","journal-title":"Circulation."},{"key":"B49","doi-asserted-by":"publisher","first-page":"4826","DOI":"10.1210\/jc.2013-2805","article-title":"Long-term cardio-and cerebrovascular events in patients with primary aldosteronism","volume":"98","author":"Mulatero","year":"2013","journal-title":"J Clin Endocrinol Metab."},{"key":"B50","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1161\/HYPERTENSIONAHA.112.197111","article-title":"Observational study mortality in treated primary aldosteronism: the German Conn's Registry","volume":"60","author":"Reincke","year":"2012","journal-title":"Hypertension."},{"key":"B51","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1016\/j.jacc.2005.01.015","article-title":"Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism","volume":"45","author":"Milliez","year":"2005","journal-title":"J Am Coll Cardiol."},{"key":"B52","doi-asserted-by":"publisher","first-page":"217","DOI":"10.3904\/kjim.2014.29.2.217","article-title":"Changes in the clinical manifestations of primary aldosteronism","volume":"29","author":"Kim","year":"2014","journal-title":"Korean J Int Med."},{"key":"B53","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/S0272-6386(99)70298-2","article-title":"Cardiovascular complications in patients with primary aldosteronism","volume":"33","author":"Nishimura","year":"1999","journal-title":"Am J Kidney Dis."}],"container-title":["Frontiers in Cardiovascular Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2022.882330\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,23]],"date-time":"2022-05-23T05:02:07Z","timestamp":1653282127000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2022.882330\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,23]]},"references-count":53,"alternative-id":["10.3389\/fcvm.2022.882330"],"URL":"https:\/\/doi.org\/10.3389\/fcvm.2022.882330","relation":{},"ISSN":["2297-055X"],"issn-type":[{"value":"2297-055X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,23]]},"article-number":"882330"}}